王宝莲, 扈金萍, 盛 莉, 陈 晖, 李 燕. HPLC-MS/MS法定量研究比格犬灌胃替诺福韦酯后替诺福韦血浆药代动力学J. 药学学报, 2013,48(3): 390-394.
引用本文: 王宝莲, 扈金萍, 盛 莉, 陈 晖, 李 燕. HPLC-MS/MS法定量研究比格犬灌胃替诺福韦酯后替诺福韦血浆药代动力学J. 药学学报, 2013,48(3): 390-394.
WANG Bao-lian, HU Jin-ping, SHENG Li, CHEN Hui, LI Yan. Pharmacokinetics of tenofovir in Beagle dogs after oral dosing of tenofovir dipivoxil fumarate using HPLC-MS/MS analysisJ. 药学学报, 2013,48(3): 390-394.
Citation: WANG Bao-lian, HU Jin-ping, SHENG Li, CHEN Hui, LI Yan. Pharmacokinetics of tenofovir in Beagle dogs after oral dosing of tenofovir dipivoxil fumarate using HPLC-MS/MS analysisJ. 药学学报, 2013,48(3): 390-394.

HPLC-MS/MS法定量研究比格犬灌胃替诺福韦酯后替诺福韦血浆药代动力学

Pharmacokinetics of tenofovir in Beagle dogs after oral dosing of tenofovir dipivoxil fumarate using HPLC-MS/MS analysis

  • 摘要:

    本研究应用HPLC-MS/MS技术建立比格犬血浆替诺福韦的定量测定方法, 并用于比格犬灌胃两种 替诺福韦酯后的血浆药代动力学和等效性研究。液相色谱分离采用Zorbax SB-C18 (3.5 μm, 100 mm × 2.1 mm, Agilent, USA) , 流动相为甲醇/ (0.3% 甲酸), 梯度洗脱, 流速为0.2 mL·min−1; 质谱检测采用电喷雾 (ESI) 离子源, 正离子选择离子检测 (SRM) 方式检测。血浆样品经20% 三氯乙酸沉淀蛋白、高速离心后进样分析, 检测反应为m/z 288.1176.2 (替诺福韦), m/z 274.1162.2 (阿德福韦, 内标)。经方法学验证, 替诺福韦在犬血浆 中线性关系良好 (105 000 ng·mL−1), 日内和日间精密度6.3%、回收率高且血浆样品稳定性好, 表明该测定 方法特异、快速、准确、可靠, 可满足替诺福韦比格犬血浆动力学研究需要。8只比格犬采用2×2交叉给药, 分别单剂量灌胃受试药物富马酸替诺福韦双特戊酯 (BP0018) 和参比药物富马酸替诺福韦二吡呋酯。与参比药物相比, 比格犬单次灌胃BP0018, 替诺福韦的平均滞留时间 (MRT) 和消除半衰期 (t1/2z) 略有延长, AUC0−tAUC0−∞Cmaxtmax均无显著差异 (DAS2.0等效性统计分析), 提示比格犬单次灌胃BP0018和富马酸替诺福韦二吡呋酯后产物替诺福韦的血浆药代动力学无显著差异, 两药基本生物等效。

     

    Abstract:

    A simple, rapid and sensitive method was developed for the quantification of tenofovir in plasma of Beagle dogs using HPLC-MS/MS analysis.  The analytes tenofovir and internal standard (IS) adefovir were separated on a Zorbax SB-C18 column (3.5 μm, 100 mm × 2.1 mm, Agilent, USA) with mobile phase of methanol/water containing 0.3% formic acid using a gradient elution mode at a flow rate of 0.2 mL·min−1.  The plasma sample preparation was a simple deproteinization by the addition of 20% trichloroacetic acid followed by centrifugation.  The detection was performed in positive selected reaction monitoring (SRM) mode with an electrospray ionization (ESI) source.  The reactions monitored were m/z 288.1−176.2 for tenofovir and m/z 274.1−162.2 for adefovir (IS).  Linear detection responses were obtained for tenofovir ranging from 10 to 5 000 ng·mL−1.  The intra- and inter-day precisions (RSD%) was no more than 6.3% with high recovery and good stability for the quantification, indicating the present method was specific, fast, accurate and reliable.  The method was successfully applied to the pharmacokinetic study of two tenofovir agents.  Tenofovir dipivoxil fumarate (BP0018, test agent) and tenofovir disoproxil fumarate (reference agent) were orally administrated to 8 Beagle dogs according to the 2×2 crossover design.  Comparing with the reference agent, the longer MRT and t1/2z were obtained in the group of BP0018, while no significant difference was observed in AUC0−t, AUC0−∞, Cmax and tmax between them, suggesting that tenofovir dipivoxil fumarate was bioequivalent to the tenofovir disoproxil fumarate in Beagle dogs.

     

/

返回文章
返回